Keyphrases
Electroconvulsive Therapy
100%
Major Depressive Disorder
69%
Treatment-resistant Depression
62%
Older Adults
54%
Transcranial Magnetic Stimulation
50%
Repetitive Transcranial Magnetic Stimulation (rTMS)
38%
Antidepressants
31%
Late-life Depression
28%
Treatment-resistant
23%
Executive Function
23%
Treatment Outcome
22%
Third Trimester
21%
Catatonia
21%
Modified Electroconvulsive Therapy
21%
Intermittent theta Burst Stimulation (iTBS)
19%
Optimizing Outcomes
19%
Design Characteristics
19%
Clinical Practice
19%
Treatment Characteristics
19%
Right Unilateral
18%
Clinical Trials
16%
Executive Function Deficits
14%
Target Engagement
14%
Depressive Symptoms
13%
Psychiatry
12%
Vagus Nerve Stimulation
12%
Pregnant Women
12%
Antidepressant Treatment
12%
Second Trimester of Pregnancy
11%
Bupropion
11%
Academic Medical Centers
10%
Hamilton Depression Rating Scale (HAM-D)
10%
Older Patients
10%
Response Predictors
10%
Sham
9%
Remission
9%
Long-term Maintenance Therapy
9%
Randomized Sham-controlled Trial
9%
Multicenter Randomized Controlled Trial
9%
Multimodal Assessment
9%
Geriatric Psychiatry
9%
Buprenorphine
9%
Disease Case
9%
Threatened Preterm Birth
9%
Depressive Symptom Trajectory
9%
Takotsubo Cardiomyopathy
9%
United States
9%
Maxillofacial
9%
Hip Fracture
9%
Geriatric Depression
9%
Medicine and Dentistry
Electroconvulsive Therapy
81%
Transcranial Magnetic Stimulation
40%
Major Depressive Episode
39%
Treatment Resistant Depression
30%
Antidepressant
24%
Third Trimester Pregnancy
21%
Executive Function
19%
Repetitive Transcranial Magnetic Stimulation
19%
Catatonia
19%
Late Life Depression
18%
Bupropion
14%
Adverse Event
14%
Psychiatry
12%
Second Trimester Pregnancy
11%
Psychological Well-Being
11%
Montgomery-Åsberg Depression Rating Scale
11%
Randomized Controlled Trial
10%
Clinical Trial
9%
Buprenorphine
9%
Low Drug Dose
9%
Psychogeriatrics
9%
Coronary Artery Disease
9%
Aortic Stenosis
9%
Implant
9%
Premature Labor
9%
Takotsubo Cardiomyopathy
9%
Acute Coronary Syndrome
9%
Monotherapy
9%
Aripiprazole
9%
Nortriptyline
7%
Randomized Clinical Trial
7%
Drug Therapy
7%
Hamilton Rating Scale for Depression
6%
Dorsolateral Prefrontal Cortex
6%
Adverse Effect
6%
Clinician
5%
Headache
5%
Antidepressant Medication
5%
Neuroscience
Transcranial Magnetic Stimulation
78%
Major Depressive Disorder
57%
Antidepressant
46%
Treatment-Resistant Depression
38%
Executive Function
31%
Electroconvulsive Therapy
25%
Late Life Depression
23%
Depressive Disorder
13%
Vagus Nerve Stimulation
12%
Venlafaxine
12%
Hamilton Rating Scale for Depression
10%
Randomized Controlled Trial
10%
Buprenorphine
9%
Executive Dysfunction
9%
Electrical Brain Stimulation
9%
Tryptophan
9%
Psychosomatic Medicine
9%
Nitrous Oxide
9%
Brain Network
9%
Placebo
8%
Mental Disorder
7%
Drug Therapy
7%
Bipolar Disorder
6%
Beck Depression Inventory
6%
Dorsolateral Prefrontal Cortex
6%
